Massive 80% Capital Reduction and Postponement of EGM
GeneOne Life Science decided to reduce capital by merging 72,706,326 common shares (80%) without payment to cover deficits, reducing capital after reduction to 18.1 billion won (record date changed from June 14 to June 15, 2026)
Extraordinary general meeting postponed from April 30 to May 28, 2026, and proxy solicitation agent changed from KDM Holdings to WIS Company Works
KOSPI Filing Information
Filing: [Correction of Description] Proxy Solicitation Reference Documents